UPDATE: Experts are raising alarms that the recent drug deals initiated by the Trump administration, branded as TrumpRx, are unlikely to provide significant savings for most Americans. Just announced, these agreements aim to offer discounts for cash-paying customers but may mainly benefit those with Medicaid coverage.
The Trump administration has struck deals with 14 pharmaceutical companies since September 30, primarily targeting tariff relief. However, experts assert that most insured patients will find better financial relief through their insurance plans rather than the new self-pay platform, TrumpRx.
According to Juliette Cubanski, deputy director at the KFF, “Most people with insurance coverage will continue to be better off using their insurance to obtain medications.” The deals specifically impact Medicaid, which traditionally has minimal copays. With these agreements, drug prices are linked to those paid in other wealthy countries, but the details about which drugs are included remain sparse.
Notably, the administration has publicized a few selected medications, including Merck’s Januvia and Gilead Sciences’ Epclusa, but many of these are not among the highest-cost drugs. Art Caplan, a medical ethics professor, emphasized that “without a full list of drugs, it’s challenging to assess the overall impact.”
Some drugs, such as Epclusa, are already available as generics, potentially reducing the impact of TrumpRx. Furthermore, the expected price reductions are steep yet may still leave many patients facing significant out-of-pocket costs. For instance, Epclusa will cost $2,425 for cash payers through TrumpRx, down from $24,920. Similarly, the average monthly cost for Wegovy and another weight-loss drug, Zepbound, will decrease from $500 to $350, and then to $250 over the next two years.
Despite these reductions, experts caution that many patients, especially those without insurance or those with high-deductible plans, may still struggle to afford medications. Stacie Dusetzina, a health policy professor, pointed out that even with discounts, “we’re usually talking about hundreds of dollars per fill, and that ends up being a real problem for most people.”
Critics are also skeptical about the authenticity of these deals. Richard Frank from the Brookings Institution suggested that the proposed price cuts could merely be repackaged discounts that drugmakers were already planning. “Until we see actual contracts committing to price changes, it’s hard to say anything will happen,” he asserted.
The administration has yet to disclose a comprehensive figure on anticipated savings for patients. A White House spokesperson indicated that some lower prices will be available via TrumpRx “early this year” and for Medicaid beneficiaries “in the coming months.” However, the lack of transparency raises questions about the deals’ effectiveness in providing meaningful relief.
As drug prices continue to soar, with an average increase of around 4% this year, many Americans are left wondering how they will afford their medications. With health insurance premiums spiking and enhanced Affordable Care Act subsidies expiring, this situation is increasingly dire.
Experts stress that without affordable health insurance, accessing prescription drugs—even at discounted rates—might remain out of reach for many. The potential savings from these deals are still unclear, particularly for Medicaid enrollees who already have low-cost access to medications.
As the situation develops, the impact of TrumpRx on American drug spending remains to be seen. For now, many patients are advised to assess their options carefully and remain informed of the evolving landscape of drug pricing in the U.S.
